Pardis Tabaee Damavandi1,2, Martin T Dove2, Richard W Pickersgill1. 1. a Queen Mary University of London , School of Biological and Chemical Sciences , London , UK. 2. b Queen Mary University of London , School of Physics and Astronomy , London , UK.
Abstract
BACKGROUND: Sporadic fatal insomnia (sFI) is a rapid progressive neurodegenerative disease characterised by gradual to perpetual insomnia, followed by dysautonomia, coma and death. 1 The cause of sFI was recently mapped to a mutation in a protein, the prion, found in the human brain. It is the unfolding of the prion that leads to the generation of toxic oligomers that destroy brain tissue and function. Recent studies have confirmed that a methionine mutation at codon 129 of the human Prion is characteristic of sFI. Current treatment slows down the progression of the disease, but no cure has been found, yet. METHODS: We used Molecular Docking and Molecular Dynamics simulation methods, to study the toxic Fatal-Insomnia-prion conformations at local unfolding. The idea was to determine these sites and to stabilise these regions against unfolding and miss-folding, using a small ligand, based on a phenothiazine "moiety". CONCLUSION: As a result we here discuss current fatal insomnia therapy and present seven novel possible compounds for in vitro and in vivo screening.
BACKGROUND:Sporadic fatal insomnia (sFI) is a rapid progressive neurodegenerative disease characterised by gradual to perpetual insomnia, followed by dysautonomia, coma and death. 1 The cause of sFI was recently mapped to a mutation in a protein, the prion, found in the human brain. It is the unfolding of the prion that leads to the generation of toxic oligomers that destroy brain tissue and function. Recent studies have confirmed that a methionine mutation at codon 129 of the humanPrion is characteristic of sFI. Current treatment slows down the progression of the disease, but no cure has been found, yet. METHODS: We used Molecular Docking and Molecular Dynamics simulation methods, to study the toxic Fatal-Insomnia-prion conformations at local unfolding. The idea was to determine these sites and to stabilise these regions against unfolding and miss-folding, using a small ligand, based on a phenothiazine "moiety". CONCLUSION: As a result we here discuss current fatal insomnia therapy and present seven novel possible compounds for in vitro and in vivo screening.
Entities:
Keywords:
Fatal Familial Insomnia; TSE; drug therapy; phenothiazinic derivatives; prions
Authors: Jennifer L Blase; Laura Cracco; Lawrence B Schonberger; Ryan A Maddox; Yvonne Cohen; Ignazio Cali; Ermias D Belay Journal: Pediatrics Date: 2014-02-02 Impact factor: 7.124
Authors: Yong Huang; Hideaki Okochi; Barnaby C H May; Giuseppe Legname; Stanley B Prusiner; Leslie Z Benet; B Joseph Guglielmo; Emil T Lin Journal: Drug Metab Dispos Date: 2006-03-31 Impact factor: 3.922
Authors: Igor Klyubin; Andrew J Nicoll; Azadeh Khalili-Shirazi; Michael Farmer; Stephanie Canning; Alexandra Mably; Jacqueline Linehan; Alexander Brown; Madeleine Wakeling; Sebastian Brandner; Dominic M Walsh; Michael J Rowan; John Collinge Journal: J Neurosci Date: 2014-04-30 Impact factor: 6.167
Authors: Andreas Noack; Sandra Noack; Andrea Hoffmann; Katia Maalouf; Manuela Buettner; Pierre-Olivier Couraud; Ignacio A Romero; Babette Weksler; Dana Alms; Kerstin Römermann; Hassan Y Naim; Wolfgang Löscher Journal: PLoS One Date: 2014-02-04 Impact factor: 3.240
Authors: Sina Ghaemmaghami; Misol Ahn; Pierre Lessard; Kurt Giles; Giuseppe Legname; Stephen J DeArmond; Stanley B Prusiner Journal: PLoS Pathog Date: 2009-11-26 Impact factor: 6.823